Strathspey Crown Holdings Group, LLC Provides Clarifying Statement Regarding Form 4 Filing with SEC for Holdings in AEON Biopharma
August 16, 2023 07:00 ET
|
AEON Biopharma
The 7,380,394 AEON shares reflected in the Form 4 filed on August 14th were transferred to limited partners of Strathspey Crown Strathspey Crown did not sell any AEON shares to the public as part...
AEON Biopharma Announces Closing of Business Combination with Priveterra Acquisition Corp. and Provides Pipeline Update
July 24, 2023 07:00 ET
|
AEON Biopharma
Common stock and warrants of combined company will be listed on the New York Stock Exchange American under the symbols AEON and AEON WS, respectively Phase 2 topline data with ABP-450 for the...
AEON Biopharma and Priveterra Announce Arrangement of Up to $125 Million of Financing in Connection with Proposed Business Combination
June 30, 2023 08:00 ET
|
AEON Biopharma
IRVINE, Calif., June 30, 2023 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin...
AEON Biopharma to Host Key Opinion Leader Webinar on Past, Present, and Potential Future Treatments for Migraine on February 24th
February 14, 2023 08:00 ET
|
AEON Biopharma
IRVINE, Calif., Feb. 14, 2023 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin...
AEON Biopharma Confirms Development Strategy and Timelines for ABP-450 Unaffected by Korean Court Ruling on Dispute Between Medytox and Daewoong Pharmaceutical
February 10, 2023 22:24 ET
|
AEON Biopharma
IRVINE, Calif., Feb. 10, 2023 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin...
AEON Biopharma and Priveterra Acquisition Corp. Announce Additional Capital Commitment from Existing Investors for at Least $20 Million
January 10, 2023 07:30 ET
|
AEON Biopharma
IRVINE, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin...
AEON Biopharma Completes Enrollment in Phase 2 Trial of ABP-450 for Preventive Treatment of Episodic Migraine
December 21, 2022 07:30 ET
|
AEON Biopharma
– Topline data expected to be announced in 2H 2023 – – Topline data from the Company’s Phase 2 trial in preventive treatment of chronic migraine expected to be announced in 1H 2024 – IRVINE,...
AEON Biopharma to Become Publicly Listed via Merger with Priveterra Acquisition Corp.; Accelerating Clinical Development of ABP-450 (prabotulinumtoxinA) Injection to Treat Debilitating Medical Conditions in Neurology
December 13, 2022 07:00 ET
|
AEON Biopharma
– Positive topline data from Phase 2 study of ABP-450 for cervical dystonia announced in September 2022 – – Topline data from Phase 2 study of ABP-450 for episodic migraine expected in Q4 2023 – ...
AEON Biopharma Reports Positive Topline Results from Phase 2 Clinical Trial of ABP-450 (prabotulinumtoxinA) in Cervical Dystonia
September 23, 2022 07:00 ET
|
AEON Biopharma
– Phase 2 trial met primary and secondary endpoints with statistical significance in reducing signs and symptoms associated with cervical dystonia (CD) in adults – – All three dosing arms...
AEON Biopharma Raises $30 Million from Insiders
August 03, 2022 07:30 ET
|
AEON Biopharma
IRVINE, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”), a private clinical-stage biopharmaceutical company focused on the development of its proprietary...